Aclaris Therapeutics (NASDAQ:ACRS) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.80), Fidelity Earnings reports. Aclaris Therapeutics had a negative net margin of 979.65% and a negative return on equity of 81.40%. The business had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $5.87 million.
Aclaris Therapeutics stock traded up $0.26 during trading hours on Friday, reaching $1.95. 1,645,800 shares of the stock were exchanged, compared to its average volume of 1,044,826. The stock has a market cap of $70.33 million, a P/E ratio of -0.48 and a beta of 0.97. Aclaris Therapeutics has a 52-week low of $0.74 and a 52-week high of $11.84. The firm’s 50 day moving average is $1.46 and its 200 day moving average is $2.77. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.22 and a current ratio of 3.23.
Several analysts recently commented on the stock. ValuEngine downgraded shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. Leerink Swann upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, October 22nd. Svb Leerink upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, October 22nd. Finally, JMP Securities downgraded shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, September 6th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $6.50.
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Further Reading: Why do earnings reports matter?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.